Abstract
Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.
Keywords: Bone mineral density, osteoporosis, rheumatoid arthritis, TNF α antagonists.
Current Drug Targets
Title:The Effects of TNF α Antagonist Therapy on Bone Metabolism in Rheumatoid Arthritis: A Systematic Review
Volume: 14 Issue: 13
Author(s): Rajalingham Sakthiswary and Srijit Das
Affiliation:
Keywords: Bone mineral density, osteoporosis, rheumatoid arthritis, TNF α antagonists.
Abstract: Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.
Export Options
About this article
Cite this article as:
Sakthiswary Rajalingham and Das Srijit, The Effects of TNF α Antagonist Therapy on Bone Metabolism in Rheumatoid Arthritis: A Systematic Review, Current Drug Targets 2013; 14 (13) . https://dx.doi.org/10.2174/13894501113149990176
DOI https://dx.doi.org/10.2174/13894501113149990176 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Measures of Disease Activity in Rheumatoid Arthritis: A Clinicians Guide
Current Rheumatology Reviews L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) Design of Cathepsin K Inhibitors for Osteoporosis
Current Topics in Medicinal Chemistry Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets Editorial [Pharmacology and Therapeutic Activity of Purinergic Drugs for Disorders of the Nervous System]
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells in Cartilage Repair: State of the Art and Methods to monitor Cell Growth, Differentiation and Cartilage Regeneration
Current Medicinal Chemistry Lifestyle Modification in Rheumatoid Arthritis: Dietary and Physical Activity Recommendations Based on Evidence
Current Rheumatology Reviews Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Application of ImageJ Software for the Quantification of Hand Joint Space Narrowing in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Generation of the Fluorescent HMGB1-GFP Fusion Protein in Insect Cells and Evaluation of its Immunogenicity in Two Mice Models
Protein & Peptide Letters ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents